Adjuvant therapy combining ovarian suppression with an aromatase inhibitor—a class of drugs typically only recommended for postmenopausal patients—may be more beneficial for premenopausal patients with breast cancer than tamoxifen.
A small study led by investigators from Brigham and Women’s Hospital suggests that the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine hydrochloride may be as effective as low-dose estradiol for relief of hot flashes.
According to a recent study in Menopause, women who go through natural menopause at ages 40 to 45 may be at increased risk of developing heart failure and smoking may produce a similar risk among those who experience menopause at ages 46 to 49.
Early menopause—whether natural or surgical—may be associated with negative effects on cognitive function that are not entirely offset by postmenopausal hormone therapy (HT), according to a new study in BJOG.
Women undergoing the menopausal transition may be prone to prolonged bleeding with periods of heaviness, according to a new study in BJOG.
A study from The American Journal of Clinical Nutrition is the basis for this article in Woman's Day. A link to the North American Menopause Society’s website is offered in the introduction, but not one to the study abstract itself.
Taking hormone replacement therapy (HRT) for at least 6 months after total knee arthroplasty (TKA) or total hip arthroplasty (THA) may reduce risk of repeat surgery. So say the results of a community-based cohort study of women in the UK who had undergone TKA or THA for osteoarthritis.
Women should not feel that they need to log long hours of vigorous exercise to see any benefits, says a study from Spain.
An ob/gyn continues to fill prescriptions for HRT despite a patient's breast cancer diagnosis.
The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.